Baird has recently raised Catalent Inc (CTLT) stock to Outperform rating, as announced on November 16, 2023, according to Finviz. Earlier, on September 5, 2023, Argus had raised the stock from a Hold ...
CIBC Asset Management Inc grew its holdings in shares of Catalent, Inc. (NYSE:CTLT – Free Report) by 7.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities ...
European Union antitrust officials are asking rival pharmaceuticals firms for their input on Novo Holdings planned $16.5 ...
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
The CEO of pharmaceuticals giant Roche said authorities should block the takeover of contract drug manufacturer Catalent by ...
The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, ...
Catalent (NYSE:CTLT – Get Free Report) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a report ...
Zacks.com on MSN13d
Catalent's Stock Gains Despite Q1 Earnings Miss, Gross Margin UpCTLT's solid segmental results led to an encouraging fiscal first-quarter performance, driving share prices in after-hours ...
On Friday, Catalent Inc (CTLT) stock saw a decline, ending the day at $59.41 which represents a decrease of $-0.51 or -0.85% from the prior close of $59.92. The stock opened at $59.81 and touched a ...
Catalent, a leading contract drug manufacturer, issued an open letter on Monday to reassure customers that a proposed $16.5 billion deal — in which it would be acquired by Novo Nordisk’s ...
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
European Union seeks input from rival pharmaceutical firms on Novo Holding $16.5 billion acquisition of Catalent.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback